Antibody Therapies
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
46
NCT05601219
A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 15, 2022
Completion: Oct 30, 2024
Loading map...